Decreasing acute peripheral neuropathy in patients treated with Oxaliplatin (heated oxaliplatin versus oxaliplatin on room temperature)
Withdrawn
- Conditions
- acute peripheral neuropathy10034606
- Registration Number
- NL-OMON32647
- Lead Sponsor
- Sint Antonius Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Age 18 - 70 years
Treated with Oxaliplatin mono or in combination with other chemotherapeutical drugs or angiogenesis inhibitors.
Adjuvant or palliative treatment for colorectal carcinoma
Patients live within a radius of 30 km from the hospital
Exclusion Criteria
Patients with diabetes mellitus, renal failure, alcoholism, vitamin B 12 deficiency, other neoplasm and HIV.
Patients who are treated in an early stage, with a cytostatic with a neurotoxicity profile.
Patients with an already existing peripheral neuropathy
Patients with congenital peripheral neuropathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Main study parameters/endpoints:<br /><br>About 40% of the patients treated with oxaliplatin will suffer from acute<br /><br>peripheral neuropathy. This study will be successful if the complaints of<br /><br>patients in the intervention group can be reduced with 50%. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary objects<br /><br>Is there a difference in severity of acute peripheral neuropathy and quality of<br /><br>life between the intervention and the standard group of patients?<br /><br>Is there a correlation between the severity of acute peripheral neuropathy and<br /><br>the quality of life in both groups</p><br>